METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF THROMBOSIS IN PATIENTS SUFFERING FROM A MYELOPROLIFERATIVE NEOPLASM
Thrombosis is the main cause of morbidity and mortality in patients with JAK2V617F positive myeloproliferative neoplasms (MPN). Recent works reported the presence of JAK2V617F in endothelial cells in some MPN patients. Here, the inventors show that JAK2V617F endothelial cells promote thrombosis through induction of endothelial P-selectin expression and thus demonstrate that P-selectin blockade was sufficient to reduce the increased propensity of thrombosis. Accordingly the present invention relates to a method of treating thrombosis in a patient suffering from a myeloproliferative neoplasm comprising administering to the patient a therapeutically effective amount of a P-selectin antagonist.
- Haematologica. 2019 Jan;104(1):70-81. doi: 10.3324/haematol.2018.195321. Epub 2018 Aug 31.